RedHill Biopharma (RDHL) Change in Account Payables (2016 - 2023)

RedHill Biopharma (RDHL) has reported Change in Account Payables for 8 consecutive years, with -$1.3 million the latest figure, recorded in Q2 2023.

• On a quarterly basis, Change in Account Payables rose 5.93% year-over-year to -$1.3 million in Q2 2023; TTM through Jun 2023 was -$1.3 million, a 85.88% increase from a year earlier, with the FY2025 full-year figure at -$437000.0, up 79.29% from the prior year.
• Change in Account Payables was -$1.3 million for Q2 2023 at RedHill Biopharma, down from $136000.0 in the prior quarter.
• Over five years, Change in Account Payables peaked at $6.8 million in Q2 2021 and troughed at -$6.0 million in Q1 2022.
• A 5-year average of -$11777.8 and a median of $93500.0 in 2019 frame the typical range for Change in Account Payables.
• Across the five-year window, Change in Account Payables surged 2372.55% in 2020 and tumbled 402.2% in 2021, its largest moves.
• Over 5 years, Change in Account Payables stood at -$610000.0 in 2019, then jumped by 917.05% to $5.0 million in 2020, then plunged by 171.85% to -$3.6 million in 2021, then surged by 84.53% to -$554000.0 in 2022, then slumped by 126.35% to -$1.3 million in 2023.
• The last three Change in Account Payables figures came in at -$1.3 million (Q2 2023), $136000.0 (Q1 2023), and -$554000.0 (Q4 2022), per Business Quant data.